Skip to main content

Albers Jeffrey W.'s Form 4 filing

Blueprint Medicines Corp (BPMC) · filed Sep 29, 2023

Accession no.
0001415889-23-013648
Filed
Sep 29, 2023
Trade date
Sep 27-28, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.24M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Albers Jeffrey W.CIK 0001638474Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 27, 2023Common StockMOption exerciseAcquired+18,102$1.87+$33,850.74194,152Direct
Sep 27, 2023Common StockSSaleDisposed−5,600$48.84F2−$273,504188,552Direct
Sep 27, 2023Common StockSSaleDisposed−12,102$49.93F3−$604,252.86176,450Direct
Sep 27, 2023Common StockSSaleDisposed−400$50.50F4−$20,200176,050Direct
Sep 28, 2023Common StockMOption exerciseAcquired+6,898$1.87+$12,899.26182,948Direct
Sep 28, 2023Common StockSSaleDisposed−6,898$50.17F5−$346,072.66176,050Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 27, 2023Common StockMOption exerciseDisposed−18,102$0.00$051,971Direct
Sep 28, 2023Common StockMOption exerciseDisposed−6,898$0.00$045,073Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $48.32 to $49.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $49.40 to $50.27 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $50.46 to $50.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $50.00 to $50.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)